Table 2.

Summary of time-to-progression (TTP), progression-free survival (PFS) and overall survival OS in patients received one dose of treatment (n = 23)

	RECIST 1.1	mRECIST	OS
Time-to-progression (weeks)
Subject who progressed	21 (91.3%)	21 (91.3%)
Number of censoring	2 (8.7%)	2 (8.7%)
Median time (95% CI)	6.0 (5.86, 6.00)	6.0 (6.00, 6.14)
Min, Max	3.3, 18.0	3.3, 18.0
Progression-free survival (weeks)
Subject who progressed/died	22 (95.7%)	23 (100.0%)
Number of censoring	1 (4.3%)	0 (0.0%)
Median time (95% CI)	6.0 (5.86, 6.00)	6.0 (6.00, 6.14)
Min, Max	3.3, 19.1	3.3, 22.3
Overall survival (weeks)
Subjects who died			21 (91.3%)
Number of censoring			2 (8.7%)
Median time (95% CI)			23.7 (19.14, 34.14)
Min, Max			8.3, 91.6